Latest News

30

June 2020

iX Biopharma’s Xativa™ records robust uptake from initial production runs in Australia...

Read On

09

June 2020

iX Biopharma Ltd is pleased to announce that the United States Patent and Trademark Office has issued a notice of allowance for its patent…

Read On

Our Sublingual Technology

Sublingual wafer administration offers the convenience of use over oral delivery, circumventing the drug breakdown in liver or gastrointestinal tract. The technology also provides rapid absorption, achieving maximum desirable therapeutic effect in a non-invasive manner.

Read On

Contact us

iX Biopharma Ltd

1 Kim Seng Promenade
#14-01 Great World City East Tower
Singapore 237994
T: +65 6235 2270
F: +65 6235 2170
E: info@ixbiopharma.com